rs121913529
|
|
|
0.020 |
GeneticVariation |
BEFREE |
KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
|
31085763 |
2019 |
rs121913529
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
|
27127178 |
2016 |
rs121913240
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Mutations in RAS genes (HRAS G13R, KRAS G12D, KRAS Q61R, NRAS Q61R) were detected in benign lesions and HRAS Q61R, NRAS Q61K mutations in PTCs.
|
31085772 |
2019 |
rs121913238
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutations in RAS genes (HRAS G13R, KRAS G12D, KRAS Q61R, NRAS Q61R) were detected in benign lesions and HRAS Q61R, NRAS Q61K mutations in PTCs.
|
31085772 |
2019 |
rs121913240
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The BRAF T1799A mutation was detected in 10 PTC cases, while two different NRAS mutations in codon 61 (C181A and A182G) were found in 2 PTC cases.
|
30361901 |
2018 |
rs712
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These results supported the role of the KRAS rs712 polymorphism as a potential genetic biomarker for the extension of PTC.
|
25201577 |
2014 |
rs1137282
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found rs11246050 in NLRP6 (dominant model, OR/95% CI: 2.028/1.091-3.769, p = 0.025), rs2286742 and rs3740530 in HABP2 (recessive model, OR/95% CI: 9.644/1.307-71.16, p = 0.026 and 3.989/1.413-11.26, p = 0.009), rs2736098 in TERT (recessive model, OR/95% CI: 2.322/1.028-5.242. p = 0.042) and rs62054619 in GAS8-AS1 (recessive model, OR/95% CI: 2.219/1.067-4.617, p = 0.033) were associated with the risk of PTC. rs1137282 in KRAS (dominant model, OR/95% CI: 0.5430/0.3192-0.9236, p = 0.024), rs1347591 and rs4461062 in NUP93 (dominant model, OR/95% CI: 0.6121/0.4128-0.9076, p = 0.015 and 0.6156/0.4157-0.9117, p = 0.015) were associated with low risk of distant metastatic disease in PTC patients. rs33954691 in TERT was associated with the risk of RR-PTC under dominant model (OR/95% CI: 3.161/1.596-6.262).
|
30826992 |
2019 |